Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02719613
Title Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | ESP | CAN | BEL | AUS


No variant requirements are available.